Medicare Enrolled
Dr. Podduturu Reddy, M.D., M.P.H.
Pulmonary Disease · Port Huron, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Reddy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reddy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reddy
Dr. Podduturu Reddy is a pulmonary disease specialist in Port Huron, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Reddy performed 23,810 Medicare services across 1,467 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reddy received a total of $432,822 from 41 pharmaceutical and/or device companies across 932 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reddy is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in MI
$432,822 industry payments
Medicare Practice Summary
Medicare Utilization ↗23,810
Medicare services
Top 1% in MI for pulmonary disease
1,467
Unique beneficiaries
$45
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,190 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Omalizumab injection (Xolair) for asthma/allergy | 17,895 | $30 | $47 |
| Injection, benralizumab, 1 mg | 2,370 | $132 | $220 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
932 | $10 | $150 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
834 | $88 | $145 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
477 | $91 | $179 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
289 | $61 | $107 |
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
155 | $6 | $46 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
139 | $128 | $315 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
103 | $62 | $109 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
90 | $14 | $30 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
79 | $27 | $116 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
68 | $38 | $91 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
64 | $31 | $103 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
64 | $41 | $103 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
56 | $114 | $212 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
43 | $121 | $190 |
| Exercise stress test A test that monitors the heart and lungs while the patient exercises to evaluate their function under physical stress. |
36 | $99 | $302 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
25 | $100 | $273 |
| Hemoglobin measurement, per day | 23 | $9 | $19 |
| Nitric oxide gas level test A test that measures the level of nitric oxide gas in the body. |
23 | $11 | $40 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
17 | $8 | $59 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
15 | $431 | $750 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
13 | $453 | $850 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$432,822
Total received (2018-2024)
Avg $61,832/year across 7 years
Top 0% in MI for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
932
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$403,033 (93.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$20,892 (4.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,897 (2.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$20,562
2023
$20,576
2022
$32,428
2021
$55,332
2020
$24,778
2019
$141,905
2018
$137,239
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$18,561
Amgen Inc.
$1,039
Genentech USA, Inc.
$244
Grifols USA, LLC
$133
Takeda Pharmaceuticals U.S.A., Inc.
$131
GENZYME CORPORATION
$101
Novartis Pharmaceuticals Corporation
$90
CSL Behring
$82
Vifor Pharma, Inc.
$68
HARMONY BIOSCIENCES LLC
$29
Actelion Pharmaceuticals US, Inc.
$23
Mallinckrodt Hospital Products Inc.
$22
GlaxoSmithKline, LLC.
$20
ANI Pharmaceuticals, Inc.
$19
Top 3 companies account for 96.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$200,392
Genentech USA, Inc.
$175,894
Amgen Inc.
$18,282
Regeneron Healthcare Solutions, Inc.
$17,859
Acerta Pharma LLC
$7,289
GENZYME CORPORATION
$3,902
Novartis Pharmaceuticals Corporation
$2,811
Veran Medical Technologies, Inc.
$1,457
Takeda Pharmaceuticals U.S.A., Inc.
$1,210
CSL Behring
$860
Grifols USA, LLC
$566
GlaxoSmithKline, LLC.
$335
PFIZER INC.
$202
Shire North American Group Inc
$176
Actelion Pharmaceuticals US, Inc.
$166
Boehringer Ingelheim Pharmaceuticals, Inc.
$131
Ethicon Inc.
$120
Insmed, Inc.
$106
United Therapeutics Corporation
$103
HARMONY BIOSCIENCES LLC
$101
Sunovion Pharmaceuticals Inc.
$101
Insulet Corporation
$100
Merck Sharp & Dohme LLC
$99
Vifor Pharma, Inc.
$68
Philips Electronics North America Corporation
$68
Harmony Biosciences LLC
$64
Mylan Specialty L.P.
$57
Merck Sharp & Dohme Corporation
$43
ABBVIE INC.
$33
Teva Pharmaceuticals USA, Inc.
$32
Gilead Sciences, Inc.
$28
JAZZ PHARMACEUTICALS INC.
$23
Mallinckrodt Hospital Products Inc.
$22
Cumberland Pharmaceuticals, Inc.
$20
ANI Pharmaceuticals, Inc.
$19
Phadia US Inc.
$15
Inogen, Inc.
$14
Jazz Pharmaceuticals Inc.
$14
Advanced Respiratory, Inc
$13
Mallinckrodt Enterprises LLC
$13
Pulmonx Corporation
$13
Top 3 companies account for 91.2% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSUPRA · AREXVY · AVYCAZ · Arikayce · BREO · BREZTRI · CHANTIX · CHARTIS CATHETER · CINQAIR · COLOGUARD DNA CAPTURE REAGENTS · CUVITRU · DIFICID · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Esbriet · FASENRA · GLASSIA · HYQVIA · Haegarda · Hizentra · ImmunoCAP · InogenOne · LONHALA MAGNAIR · LUMIZYME · Monarch Platform · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · Omnipod · PIFELTRO · POMPE - DISEASE · PREMARIN · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C · Prolastin-C Liquid · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUTENT · SYMBICORT · Spin · TAGRISSO · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · UTIBRON · UTIBRON NEOHALER · Utibron · Veltassa · Vibativ · WAKIX · Wakix · Wellcentive Undiv · XOLAIR · XYWAV · Xolair · Xyrem · Yupelri · Zemaira
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (93%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for pulmonary disease in MI.
Geographic Context
Pulmonary diseases within 10 mi
1
Per 100K population
0.6
County median income
$69,349
Nearest hospital
LAKE HURON MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Reddy is a mixed practice specialist, with above-average Medicare volume (top 1% in MI), with speaking/promotional industry engagement in the top 0% of MI peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Reddy experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Reddy performed 17,895 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reddy receive payments from pharmaceutical companies?
Yes. Dr. Reddy received a total of $432,822 from 41 companies across 932 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reddy's costs compare to other pulmonary diseases in Port Huron?
Dr. Reddy's average Medicare payment per service is $45. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reddy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Port Huron
Browse pulmonary diseases in Port Huron ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in MI
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in MI
Which MI pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology